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Introduction
In recent years the amino acid homocysteine has achieved 
the status of an important factor in vascular disease, dis-
eases of aging, and other fundamental processes in biology 
and medicine [25]. After its discovery in 1932, homocysteine 
was characterized as an important intermediate in methio-
nine metabolism. Little was known about its biomedical sig-
nificance until 1962, when children with mental retardation, 
accelerated growth, and propensity to thrombosis of arteries 
and veins were found to excrete homocysteine in the urine 
[19,25]. The cause of homocystinuria in most of these cases is 
deficiency of the enzyme cystathionine synthase, a pyridoxal 
phosphate-dependent enzyme [25]. In 1968, a second case of 
homocystinuria caused by deficiency of a different enzyme, 
methionine synthase, a folate and vitamin B12–dependent 
enzyme, was critical in the discovery of the atherogenic po-
tential of homocysteine [25]. McCully and Wilson proposed 
the “homocysteine theory of artheriosclerosis” in 1975 on the 
basis of pathological examinations of autopsy material from 
children with homocystinuria [20]. However, only within the 
past 5 years has homocysteine taken its place among other 
major risk factors such as cholesterol, smoking, and obesity 
[20]. Homocysteine is now widely accepted as a major inde-
pendent risk factor for cardiovascular, cerebrovascular, and 
peripheral vascular disease [13,17,20,33]. However, the pre-
cise mechanisms underlying this association, although inten-
sively studied, are still incompletely solved [30].
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Abstract
Background: Homocysteine is a sulfur-containing intermediate product in the normal metabolism of methionine, an essential amino acid. 
Hyperhomocysteinemia defines the state in which concentrations of homocysteine exceeds normal level. Homocysteine is located at a metabolic branch 
point and can either be irreversibly degraded to cysteine via the transsulfuration pathway, or conserved by remethylation back to methionine. Folic 
acid, vitamin B12, and vitamin B6 deficiencies and reduced enzyme activities inhibit the breakdown of homocysteine, thus increasing the concentration 
of intracellular homocysteine. Being cytotoxic, homocysteine is increasingly exported from the cell to become detectable in plasma. In recent years the 
amino acid homocysteine has achieved the status of an important factor in vascular disease, diseases of aging, and other fundamental processes in biology 
and medicine. Hyperhomocysteinemia may alter vascular morphology, stimulate inflammation, activate the endothelium and the blood clotting cascade, 
and inhibit fibrinolysis. As a result, hyperhomocysteinemia is associated with loss of endothelial antithrombotic function and induction of a procoagulant 
environment. The role of homocysteine in endothelial dysfunction is thought to be mediated by mechanisms including oxidative stress. Vascular injury 
could be caused by an imbalance between nitric oxide production from dysfunctional endothelial cells and homocysteine concentrations.
Conclusions: Hyperhomocysteinemia is associated with alterations in vascular morphology, loss of endothelial antithrombotic function, and induction 
of a procoagulant environment.
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Homocysteine metabolism
Homocysteine is located at a metabolic branch point and 
can either be irreversibly degraded to cysteine via the trans-
sulfuration pathway, or conserved by remethylation back to 
methionine (fig. 1) [12,30].
First, methionine is activated by the enzyme me-
thionine adenosyltransferase (MAT) and ATP to form 
S-adenosylmethionine (SAM) [30]. SAM is the primary meth-
yl group donor for many vital biological processes, including 
methylation of DNA, RNA, proteins, lipids and neurotrans-
mitters [10,11,13,16,28,29,30,31,32,33,345]. Upon transmeth-
ylation, SAM is converted to S-adenosylhomocysteine (SAH), 
which is further hydrolyzed by the enzyme adenosylhomo-
cysteine hydrolase (SAHH) to homocysteine and adenosine. 
This reaction is reversible and favors SAH synthesis [12,30]. 
The transsulfuration pathway, mainly limited to liver and 
kidneys, is initiated with the condensation of homocysteine 
and serine to form cystathionine, in a reaction catalyzed by 
the enzyme cystathionine β-synthase (CBS), with pyridoxal 
phosphate (vitamin B6) as co-factor [12,13,30,31,34]. Cys-
tathionine is further metabolized to produce cysteine by an-
other enzyme – cystathionine γ-lyase (CGL). Besides protein 
synthesis, cysteine is used in the synthesis of glutathione, an 
important cellular antioxidant also involved in detoxification 
of many xenobiotics [30].
In remethylation, homocysteine acquires a methyl group 
from 5-methyltetrahydrofolate (5-MTHF) or from betaine 
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to form methionine. The reaction with MTHF occurs in all 
tissues and is vitamin B12-dependent, while the reaction with 
betaine is confined mainly to the liver and is vitamin B12-
independent [31].
Homocysteine remethylation occurs by receiving the 
methyl group from 5-MTHF, which links the folate cycle with 
the homocysteine metabolism (fig. 1). 5-MTHF is the active 
folate derivative and the main circulating form of folate in 
plasma. It is produced from 5,10-methylenetetrahydrofolate 
(5,10-MTHF) by the enzyme 5,10-methylenetetrahydrofolate 
reductase (MTHFR), which uses flavine adenine dinucleotide 
(FAD – the active form of vitamin B2) as co-factor [1,4,33,34]. 
The methyl group from 5-MeTHF is transferred via vitamin 
B12 to homocysteine, in a reaction catalyzed by the enzyme 
methionine synthase (MTR), with production of tetrahy-
drofolate (THF) [27,30,33,34]. THF is then recycled to 5,10-
MTHF in the presence of serine and vitamin B6 by the enzyme 
serine hydroxymethyltransferase (SHMT) [30].
Over time, the cobalamin (I) cofactor of MTR is oxi-
dized to form cobalamin (II), leading to inactivation of MTR. 
Thus, the enzyme methionine synthase reductase (MTRR) 
is required for reversion of oxidized cobalamin (II) to CH3-
cobalamin (III) to maintain the activity of MTR [22]. The 
folate-dependent remethylation pathway is present in nearly 
all cells, except red blood cells [34].
Alternatively, in liver and kidney, methyl groups can also 
be donated by betaine (also known as trimethylglycine, an 
intermediate of choline oxidation), in a reaction catalyzed 
by the enzyme betaine-homocysteine methyltransferase 
(BHMT) [30].
The intracellular concentration of homocysteine is under 
tight control. Once formed in the cell, homocysteine is quick-
ly either metabolized to cysteine or remethylated to methio-
nine. In addition, if one of these pathways is compromised, 
leading to higher intracellular production than elimination, 
the excess of homocysteine is rapidly exported to the blood. 
Hence, cellular export of homocysteine reflects the balance 
between homocysteine production and catabolism. [12,30].
SAM plays a central role in the regulation of homocys-
teine metabolism, by coordinating the fate of homocysteine 
towards remethylation or transsulfuration pathways; it is an 
allosteric inhibitor of MTHFR and an activator of CBS activ-
ity. When the levels of SAM are adequate to sustain meth-
ylation demand, the partitioning of homocysteine between 
both metabolic pathways is approximately equal. In case of 
excess of methionine supply, an increase in tissue SAM levels 
occurs, and homocysteine degradation to cysteine is favored. 
Moreover, SAM also regulates homocysteine remethylation 
through inhibition of BHMT activity. Conversely, if methio-
nine levels are low, for example during fasting, low SAM lev-
els will neither activate CBS nor inhibit MTHFR, resulting in 
conservation of homocysteine via remethylation back to me-
thionine [12,16,30,31].
Folic acid, vitamin B12, and vitamin B6 deficiencies and re-
duced enzyme activities inhibit the breakdown of homocyste-
ine, thus increasing the concentration of intracellular homo-
cysteine [29,33]. Being cytotoxic, homocysteine is increasing-
ly exported from the cell to become detectable in plasma [33].
Causes of hyperhomocysteinemia
Hyperhomocysteinemia is a terminology suggested to 
describe the presence of abnormal elevation in total plasma 
homocysteine levels. In the fasting state, normal plasma levels 
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Fig. 1.  Homocysteine metabolism (A – enzyme methionine adenosyltransferase, B – enzyme 
5,10-methylenetetrahydrofolate reductase) [33]. 
 
 
Over time, the cobalamin (I) cofactor of MTR is oxidized to form cobalamin (II), leading to 
inactivation of MTR. Thus, the enzyme methionine synthase reductase (MTRR) is required for 
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Fig. 1.  Homocysteine metabolism (A – enzyme methionine adenosyltransferase,  
B – enzyme 5,10-methylenetetrahydrofolate reductase) [33].
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of homocysteine are less than 12 μmol/l [1,2,5,6,9,14,21,30]. 
Pregnant women have lower plasma tHcy than nonpregnant 
women. The mean tHcy concentration in pregnant women is 
5–6 μmol/L, and tHcy concentrations >10 μmol/L are rarely 
observed [28]. 
Table 1
Determinants of plasma tHcy [28]
Causes Effect
Genetic factors
Homocystinuria ↑↑↑
Heterozygosity for CBS defects ↑
Down syndrome ↓
MTHFR 677C→T (homozygosity) ↑
Other polymorphisms ↑
Physiologic determinants
Increasing age ↑
Male sex ↑
Pregnancy ↓
Postmenopausal state ↑
Renal function, reduced glomerular filtration 
rate
↑
Increasing muscle mass ↑
Lifestyle determinants
Vitamin intake (folate, B12, B6, B2) ↓
Smoking ↑
Coffee ↑
Ethanol intake ↑
Lack of exercise ↑
Clinical conditions
Folate deficiency ↑↑
Cobalamin deficiency ↑↑↑
Vitamin B6 deficiency ↑
Renal failure ↑↑
Hyperproliferative disorders ↑
Hypothyroidism ↑
Hyperthyroidism ↓
Early stage of diabetes ↓
Late stage of diabetes ↑
Drugs
Folate antagonists (Methotrexate, Trimethoprim, 
Anticonvulsants, Cholestyramine)
↑
Cobalamin antagonists (Nitrous oxide, Nitric 
oxide, Metformin, H2-receptor antagonists, 
Omeprazole)
↑
Vitamin B6 antagonists ↑
Sulfhydryl compounds ↓
Estrogens, Tamoxifen ↓
Androgens ↑
Cyclosporin A, Diuretics, Fibrates ↑
↓ – decrease in tHcy, ↑ – moderate hyperhomocysteinemia (12 – 30 
μmol/l), ↑↑ – intermediate hyperhomocysteinemia (30 – 100 μmol/l), 
↑↑↑ – severe hyperhomocysteinemia (>100 μmol/l)
Determinants of plasma total homocysteine (tHcy) in-
clude genetic, physiologic, and lifestyle factors; various disea-
ses and drugs (tab. 1) [9,17,28,33,34]. The causes of increased 
tHcy concentrations vary according to the age of the person 
and the degree of tHcy increase [20,27,28,33]. Low folate or 
cobalamin status or renal impairment account for the majori-
ty of cases with increased tHcy [3,11,31,32,33]. In populations 
eating food fortified with folic acid, renal impairment and 
cobalamin deficiency are the most important determinants. 
Homozygosity for the MTHFR 677C→T polymorphism is 
the most common genetic determinant. Individuals with the 
MTHFR 677TT genotype usually have higher tHcy than those 
with the 677CC variant, but it depends on the folate status. 
Most other genetic polymorphisms in enzymes related to ho-
mocysteine have little effect on tHcy concentrations [28,29].
Circulating species of homocysteine in plasma
Homocysteine is present in plasma in various forms in 
different proportions [20,27,33]. Human plasma contains 
both reduced and oxidized species of homocysteine [20]. 
The concentration of free homocysteine in plasma is very 
low and accounts for less than 2% of total plasma homocys-
teine in normal subjects [27,33] and the oxidized forms of 
homocysteine usually comprise 98–99% of total plasma ho-
mocysteine in human plasma [20]. Disulfide forms also exist 
with cysteine and with proteins containing reactive cysteine 
residues (protein-bound homocysteine). The latter oxidized 
forms are referred to as mixed disulfides. The concentration of 
homocystine and homocysteine-cysteine represents approxi-
mately 10-15%, and protein-bound homocysteine accounts 
for over 80% of the measured total homocysteine in normal 
plasma [27]. Total homocysteine, therefore, is the sum total 
of all forms of homocysteine that exist in plasma or serum 
[20]. Only minute amounts of homocysteine are found in the 
urine of healthy subjects. The term “homocystinuria” should 
therefore be reserved for inborn errors of metabolism char-
acterized by extremely elevated plasma homocysteine levels 
and substantially increased excretion of homocysteine in the 
urine [33].
Mechanisms of homocysteine-mediated vascular da-
mage
Hyperhomocysteinemia may alter vascular morphology, 
stimulate inflammation, activate the endothelium and the 
blood clotting cascade, and inhibit fibrinolysis [1,5,6,9,10,11,1
2,13,1418,33,34,35]. As a result, hyperhomocysteinemia is as-
sociated with loss of endothelial antithrombotic function and 
induction of a procoagulant environment. Most known forms 
of damage or injury are due to homocysteine-mediated oxida-
tive stresses. Chief among these are changes in the intracel-
lular redox potential, interference with the nitric oxide (NO) 
system, and activation of transcription factors with stimula-
tion of gene expression [33].
Observations in clinical and animal studies have identi-
fied potential pathophysiological targets where homocysteine 
exerts its damaging effect. Those targets include endothelial 
cells (ECs), vascular smooth muscle cells (VSMCs), connec-
tive tissue, platelets, coagulation factors, lipids, and NO signal 
transduction molecules. Unfortunately, there is not an estab-
lished, unifying hypothesis by which homocysteine evokes 
vascular damage. However, there are numerous biological and 
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biomolecular mechanisms that have been heavily studied and 
proposed to explain the pathological changes associated with 
elevated tHcy levels [34].
Oxidative stress is possibly the most detrimental stress-
or in the pathogenesis of most diseases. Studies have shown 
that the pro-oxidative homocysteine exerts direct biologi-
cal damage to vascular cells and tissue through an oxidative 
mechanism that damages lipids, nucleic acids, and proteins 
[15,18,19,23,34]. An alternative hypothesis to that of a direct 
effect of reduced homocysteine on endothelial cell injury is 
that homocysteine is acting indirectly through its oxidation 
and the concomitant production of reactive oxygen species 
[7,24].
Under aerobic conditions (in the presence of molecular 
oxygen as an electron acceptor) and at physiological pH, thi-
ols such as homocysteine, oxidize to form disulfides, accord-
ing to the general reaction:
2 Homocysteine (RSH) + O2→ Homocysteine (RSSR) + 
[O- 2] → H2O2 [19,24]
In plasma, this reaction can be catalyzed by transition 
metals such as copper and cobalt. Homocysteine can autooxi-
dize readily via general thiol oxidation mechanism described 
above and form homocystine, or oxidize other thiols such as 
cysteine and glutathione to form mixed disulfides, or oxidize 
free cysteine residues on proteins and peptides to form mixed 
disulfides [19]. Homocysteine itself has the ability to generate 
potent reactive oxygen species (ROS) when oxidized due to its 
highly reactive sulfhydryl group. In the circulation, this thiol 
undergoes rapid metal-catalyzed sulfhydryl auto-oxidation, 
leading to the generation of superoxide and hydrogen perox-
ide [15,19,20,27,34,35].
In addition to auto-oxidative ROS production, decreased 
homocysteine clearance and resultant accumulation further 
increases the production of harmful oxidants that collective-
ly spurs on the negative cascade of vascular complications. 
Homocysteine has a detrimental effect on vascular cells and 
tissues as a result of oxidative damage to lipids, nucleic acids, 
and proteins. The injurious oxidative stress exerted by homo-
cysteine relies either on auto-oxidation of the highly reactive 
thiol group of homocysteines or on the formation of intra-
cellular superoxide and peroxyl radicals with concomitant 
inhibition of cellular antioxidant enzymes, such as superoxide 
dismutase (SOD) and glutathione peroxidase [13,34].
As a consequence of homocysteine-produced oxidative 
radicals, there is a critical impairment in the production of 
endothelium derived NO by several different mechanisms 
[34,35]. Homocysteine decreases the bioavailability of NO, 
one of the major endothelium-dependent vasodilators that is 
produced by the endothelial isoform of nitric oxide synthase 
(NOS). This effect is caused either by an accelerated oxidative 
inactivation of NO and/or eNOS or by an increase in serum 
aasymmetrical dimethylarginine (ADMA), an endogenous 
inhibitor of eNOS, thus decreasing NO production [13,34,35]. 
Also, studies have shown that homocysteine suppresses NO 
production without altering NOS protein levels or enzyme ac-
tivity and the homocysteine-induced endothelial injury and 
subsequent reduction in NO production are primarily associ-
ated with increased ROS levels [34].
In the walls blood of vessels, NO contributes to the regu-
lation of systemic blood flow and pressure by activating in-
tracellular signaling pathways that modulate calcium levels 
in VSMC resulting in vasodilation. Homocysteine is known 
to decrease vascular function by the oxidative depletion of 
biologically active NO. Homocysteine has also been shown 
to cause striking changes in vessel wall structure by induc-
ing extracellular matrix alterations that fragment the arterial 
internal and medial elastic lamina. Unlike the growth retar-
dation of the endothelium, homocysteine has been associ-
ated with myointimal hyperplasia and VSMC hypertrophy 
[2,4,6,8,9,17,20,27,34,35]. It has been shown that homocyste-
ine stimulates VSMC proliferation by the activity of homo-
cysteine-generated oxygen radicals that activate cytokines 
that are active in the initial phase of the proliferative process. 
It has also been reported that the homocysteine-mediated re-
duction in NO synthesis and release by injured ECs causes the 
release of growth factors that provoke proliferation of nearby 
VSMC [34]. 
Homocysteine has been shown to induce vascular inflam-
mation by enhancing the expression of pro-inflammatory cy-
tokines, such as monocyte chemoattractant protein 1 (MCP-
1), which regulates migration and activation of monocytes/
macrophages, and interleukin 8 (IL-8), which is an important 
chemoattractant for neutrophils and T-lymphocytes [13]. 
Homocysteine has been shown to initiate the process by in-
creasing the expression and plasma levels of the inflammatory 
cytokine, tumor necrosis factor alpha (TNF-α), and enhanc-
ing the activation of a redox-sensitive nuclear inflammatory 
transcription factor, nuclear factor-kappa B (NFkB), in the 
vasculature [19,34,35].
It has long been believed that homocysteine may cause lipid 
peroxidiation by an oxidation-dependent pathway [2,4,34,35]. 
Homocysteine generates oxidative radicals that initiate oxida-
tive degradation of lipids on the EC surface, which causes loss 
of membrane function and increased permeability. Clinical 
data have shown that patients with hyperhomocysteinemia 
have an increase in end products of lipid peroxidation such as 
F2-isoprostanes and malondialdehyde [34].
A more recent concept concerns activation of the unfold-
ed protein response (UPR) that is triggered when unfolded or 
misfolded proteins accumulate in the endoplasmic reticulum 
(ER). This ER stress induces the expression of several molecu-
lar chaperones and other stress response proteins, which are 
aimed at restoring correct protein folding or retranslocating 
defective proteins back to the cytosol for degradation in the 
proteasomes. In case of a prolonged ER stress, the UPR ex-
tends to the activation of apoptosis by various signaling path-
ways. This is precisely what happens in human endothelial 
cells after exposure to homocysteine in vitro: while inducing 
misfolding in the ER by altering the local redox potential and 
interfering with disulfide bond formation, homocysteine ac-
tivates UPR and, subsequently, growth arrest and apoptosis 
(fig. 2) [13].
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These actions can be in connection with the widely be-
lieved capability of homocysteine to alter the surface prop-
erties of endothelial cells by changing their phenotype from 
anticoagulant to procoagulant [10,18,21,24,26].
Endothelial cells also possess several antithrombotic 
mechanisms to protect against intravascular thrombosis. 
However, elevated plasma homocysteine levels have been 
reported to cause an imbalance in coagulant and clotting 
properties toward a prothrombotic state in coronary and pe-
ripheral disease that is primarily mediated by the endothelial 
dysfunction [34].
In fact, physiological levels of homocysteine may enhance 
the binding of lipoprotein to fibrin. On the other hand, high 
levels of homocysteine reduce protein C activation, thus in-
hibiting its anticoagulant activity; induce a great inhibition, 
by more than 75%, of antithrombin III; inhibit the synthesis 
of anticoagulant heparan sulphate through an induced altera-
tion of the redox potential; suppress thrombomodulin and 
inactivate its co-factor activity; block tissue plasminogen ac-
tivator binding to endothelial cells; and activate tissue factor 
transcription [10,18,24,26]. 
Furthermore, it has been shown that homocysteine in-
duces the activity of a protease which activates factor V, 
thus promoting coagulation even in the absence of throm-
bin. Homocysteine rapidly reacts with nitric oxide to form 
S-nitroso-homocysteine, which acts as a potent antiplatelet 
agent; the formation of this adduct may attenuate the produc-
tion of peroxides from homocysteine, thus protecting against 
the atherogenic properties of homocysteine [10,18,19,24]. 
Vascular injury could be caused by an imbalance between 
nitric oxide production from dysfunctional endothelial cells 
and homocysteine concentrations [24,35].
Conclusions
This review focuses on disorders of homocysteine metab-
olism, on situations in which the metabolic mechanism is im-
paired and elucidates the mechanisms by which homocysteine 
can cause endothelial dysfunction. Thereby: (1) Homocysteine 
may increase oxidative stress; (2) Homocysteine may impair 
endothelial function and bioavailability of nitric oxide; (3) 
Homocysteine may impair vascular smooth muscle cell func-
tion; (4) Homocysteine may change extracellular matrix, col-
lagen structure and function; (5) Homocysteine may induce 
a prothrombotic state; (6) Homocysteine may increase lipid 
peroxidation, and increase the oxidation of lowdensity lipo-
protein; (7) Homocysteine may induce inflammation and 
apoptosis.
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